The implications of out-of-pocket cost of cancer treatment in the USA: A critical appraisal of the literature

Future Oncology

Volumn 10, Issue 14, 2014, Pages 2189-2199

  Bestvina, Christine M ^a   Zullig, Leah L ^b   Yousuf Zafar, S ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

cancer; decision making; financial distress; healthcare cost; healthcare delivery

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APPETITE STIMULANT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; FUEL; IMMUNOMODULATING AGENT; PRESCRIPTION DRUG; PROTEASOME INHIBITOR; SORAFENIB;

ABSENTEEISM; ADJUSTMENT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CAREGIVER BURDEN; CAREGIVER SUPPORT; CHRONIC MYELOID LEUKEMIA; CLOTHING; COMORBIDITY; COPING BEHAVIOR; DIET SUPPLEMENTATION; DISABILITY; DOCTOR PATIENT RELATION; DRUG COST; EMPLOYMENT; FINANCIAL MANAGEMENT; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPICE; HOSPITAL ADMISSION; HUMAN; INCOME; LEISURE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEAL; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; NURSING HOME; OUTPATIENT CARE; PARENT; PATIENT EDUCATION; PHYSICIAN; PRESCRIPTION; PRODUCTIVITY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; TRAFFIC AND TRANSPORT; TRAVEL; TREATMENT DURATION; TREATMENT REFUSAL; UNITED STATES; WORKING TIME; CAREGIVER; COST BENEFIT ANALYSIS; MEDICATION COMPLIANCE; MENTAL STRESS; META ANALYSIS; NEOPLASMS; PSYCHOLOGY; SURVIVOR;

CAREGIVERS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MEDICATION ADHERENCE; NEOPLASMS; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; RISK FACTORS; STRESS, PSYCHOLOGICAL; SURVIVORS; UNITED STATES;

EID: 84916599995     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.130     Document Type: Review

References (61)

1. Meropol Nj SK. Cost of cancer care: issues and implications. J. Clin. Oncol. 25(2), 180-186 (2007).
2. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933-980 (2011).
3. Zafar Sy PJ, Schrag D et al. The fnancial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18(4), 381-390 (2013).
4. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §2702, 124 Stat. 119, 318-319 (2010). www.hhs.gov
5. Zafar Sy AA. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 27(2), 80-81, 149 (2013).
6. Davidoff AJ, Erten M, Shaffer T et al. Out-of-pocket health care expenditure burden for Medicare benefciaries with cancer. Cancer 119(6), 1257-1265 (2013).
7. Finkelstein EA, Tangka FK, Trogdon JG, Sabatino SA, Richardson LC. The personal fnancial burden of cancer for the working-aged population. Am. J. Manag. Care. 15(11), 801-806 (2009).
8. Arozullah AM, Calhoun EA, Wolf M et al. The fnancial burden of cancer: estimates from a study of insured women with breast cancer.J. Support. Oncol. 2(3), 271-278 (2004).
9. Brooks J, Wilson K, Amir Z. Additional financial costs borne by cancer patients: a narrative review. Eur. J. Oncol. Nurs. 15(4), 302-310 (2011).
10. Palmer NR, Geiger AM, Lu L, Case LD, Weaver KE. Impact of rural residence on forgoing healthcare after cancer because of cost. Cancer Epidemiol. Biomarkers Prev. 22(10), 1668-1676 (2013).
11. Taylor JC, Terrell JE, Ronis DL et al. Disability in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 130(6), 764-769 (2004).
12. Meropol Nj SD, Smith Tj et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J. Clin. Oncol. 27(23), 3868-3874 (2009).
13. Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Womens Health Issues 15(3), 97-108 (2005).
14. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States.J. Hepatol. 50(1), 89-99 (2009).
15. SchnurJB, Graff Zivin J, Mattson DM Jr et al. Acute skin toxicky-related, out-of-pocket expenses in patients with breast cancer treated with external beam radiotherapy: a descriptive, exploratory study. Support. Care Cancer 20(12), 3105-3113 (2012).
16. Borovicka JH, Calahan C, Gandhi M et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch. Dermatol. 147(12), 1403-1409 (2011).
17. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl. 1), 4-10 (2007).
18. Wagner L, Lacey MD. The hidden costs of cancer care: an overview with implications and referral resources for oncology nurses. Clin. J. Oncol. Nurs. 8(3), 279-287 (2004).
19. Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. Value Health 14(6), 944-952 (2011).
20. Goldman DP, Jena AB, Lakdawalla DN, Malin JL, Malkin JD, Sun E. The value of specialty oncology drugs. Health Serv. Res. 45(1), 115-132 (2010).
21. Kim YA, Rascati KL, Prasla K, Godley P, Goel N, Dunlop D. Retrospective evaluation of the impact of copayment increases for specialty medications on adherence and persistence in an integrated health maintenance organization system. Clin. Ther. 33(5), 598-607 (2011).
22. Bach PB, Saltz LB, Wittes RE. In cancer care, cost matters. New York Times, 15th October 2012.
23. Cook R. Economic and clinical impact of multiple myeloma to managed care. J. Manag. Care Pharm. 14(7 Suppl.), 19-25 (2008).
24. Tomic K, Long S, Li X, Fu AC, Yu TC, Barron R. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors. J. Oncol. Pharm. Pract. 19(4), 328-337 (2013).
25. Calhoun EA, Schumock GT, Mckoy JM et al. Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited. Pharmacoeconomics 23(8), 767-775 (2005).
26. Timmons A, Gooberman-Hill R, Sharp L. "It's at a time in your life when you are most vulnerable": a qualitative exploration of the fnancial impact of a cancer diagnosis and implications for fnancial protection in health. PLoS ONE 8(11), e77549 (2013).
27. Zullig Lh PJ, Schrag D et al. Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer. J. Oncol. Pract. 9(6S), 60s-63s (2013).
28. Neugut AI, Subar M, Wilde ET et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J. Clin. Oncol. 29(18), 2534-2542 (2011).
29. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J. Clin. Oncol. 32(4), 306-311 (2014).
30. Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for fnancial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J. Clin. Oncol. 30(14), 1608-1614 (2012).
31. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 290(7), 953-958 (2003).
32. Bullock AJ, Hofstatter EW, Yushak ML, Buss MK. Understanding patients' attitudes toward communication about the cost of cancer care. J. Oncol. Pract. 8(4), e50-e58 (2012).
33. Henrikson NB, Tuzzio L, Loggers ET, Miyoshi J, Buist DS. Patient and oncologist discussions about cancer care costs. Support. Care Cancer 22(4), 961-967 (2013).
34. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey J. Clin. Oncol. 25(2), 233-237 (2007).
35. Alexander GC, Casalino LP, Tseng CW, Mcfadden D, Meltzer DO. Barriers to patient-physician communication about out-of-pocket costs. J. Gen. Intern. Med. 19(8), 856-860 (2004).
36. Bradley CJ. The need for online information on the economic consequences of cancer diagnosis, treatment, and survivorship. J. Med. Internet Res. 7(3), e29 (2005).
37. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs infuence treatment: a national survey of oncologists. Health Aff. (Millwood) 29(1), 196-202 (2010).
38. Berry SR, Bell CM, Ubel PA et al. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J. Clin. Oncol. 28(27), 4149-4153 (2010).
39. Grunfeld E, Coyle D, Whelan T et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ 170(12), 1795-1801 (2004).
40. Skalla KA, Smith EM, Li Z, Gates C. Multidimensional needs of caregivers for patients with cancer. Clin. J. Oncol. Nurs. 17(5), 500-506 (2013).
41. Hayman JA, Langa KM, Kabeto MU et al. Estimating the cost of informal caregiving for elderly patients with cancer. J. Clin. Oncol. 19(13), 3219-3225 (2001).
42. Francis LE, Worthington J, Kypriotakis G, Rose JH. Relationship quality and burden among caregivers for late-stage cancer patients. Support. Care Cancer 18(11), 1429-1436 (2010).
43. Dussel V, Bona K, Heath JA, Hilden JM, Weeks JC, Wolfe J. Unmeasured costs of a child's death: perceived fnancial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer. J. Clin. Oncol. 29(8), 1007-1013 (2011).
44. Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer 117(12), 2791-2800 (2011).
45. Darby K, Davis C, Likes W, Bell J. Exploring the fnancial impact of breast cancer for African American medically underserved women: a qualitative study. J. Health Care Poor Underserved 20(3), 721-728 (2009).
46. Park ER, Kirchhoff AC, Zallen JP et al. Childhood Cancer Survivor Study participants' perceptions and knowledge of health insurance coverage: implications for the Affordable Care Act. J. Cancer Surviv. 6(3), 251-259 (2012).
47. Kent EE, Forsythe LP, Yabroff KR et al. Are survivors who report cancer-related fnancial problems more likely to forgo or delay medical care? Cancer 119(20), 3710-3717 (2013).
48. The health care law: how it can help people with cancer and their families. www.cancer.org
49. Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifes fve key opportunities to improve care and reduce costs: the top fve list for oncology. J. Clin. Oncol. 30(14), 1715-1724 (2012).
50. Schnipper LE, Lyman GH, Blayney DW et al. American Society of Clinical Oncology 2013 top fve list in oncology. J. Clin. Oncol. 31(34), 4362-4370 (2013).
51. CancerCare. www.cancercarecopay.org
52. HealthWell Foundation. www.healthwellfoundation.org
53. Weingart SN, Brown E, Bach PB et al. NCCN Task Force Report: Oral chemotherapy J. Natl Compr. Canc. Netw. 6(Suppl. 3), S1-S14 (2008).
54. Kuppens IE, Breedveld P, Beijnen JH, Schellens JH. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest. 23(5), 443-464 (2005).
55. Ubel PA, Abernethy AP, Zafar SY. Full disclosure-out-of-pocket costs as side effects. N. Engl. J. Med. 369(16), 1484-1486 (2013).
56. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298(1), 61-69 (2007).
57. Zafar SY, Abernethy AP. Financial toxicity, Part II: how can we help with the burden of treatment-related costs? Oncology (Williston Park) 27(4), 253-254, 256 (2013).
58. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol. Biomarkers Prev. 20(10), 2006-2014 (2011).
59. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J. Natl Cancer Inst. 103(2), 117-128 (2011).
60. Carroll J. Oral/infusion cancer drug parity begins to raise health plan costs. Manag. Care 21(1), 7-8 (2012).
61. American Cancer Society. The Affordable Care Act: how it helps people with cancer and their families. http://cancer.org